This is just an opinion, but JNJ-69086420 will be killed if it...

First 149 Last

Share
Profile

Follow
Davisite

19,375 Posts.

6497

26/05/24

08:42

Post #: 74010924
Share
Originally posted by ttppxx ↑

Actinium-225 alpha therapyfrom J&J? (what we know so far - per info gleaned from an abstract due to be reported next week)

SOME BACKGROUND

Clinical Trial Title: A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Link for full details: https://clinicaltrials.gov/study/NCT04644770

[Note: JNJ-69086420 (also referred to as JNJ-6420) is an alpha-particle emitter (as opposed to Cu67 which is a beta emitter)]

Study Objectives

To determine the recommended Phase 2 dose(s) (RP2D) of JNJ-69086420 in Part 1 (Dose Escalation), and,

To determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion)

Other Trial Details

An open-label clinical trial

Targetting men 'aged ≥18 years with advanced metastatic castration-resistant prostate cancer who have previously received at least one prior androgen receptor pathway inhibitor'.

THE REPORTS - (so far)

-----
REPORT 1: ASCO: J&J's radioligand spurs responses, but 4 deaths mar early results

Link to this report: https://www.fiercebiotech.com/biotech/asco-jjs-radioligand-spurs-responses-4-deaths-mar-early-result

Findings (summary) - almost verbatim

64 patients received at least one dose of JNJ-6420, with safety data being recorded for 57 who had received 150 μCi.

35(61%) experienced grade 3 or higher treatment-emergent adverse events (TEAEs), and 21(37%) had a serious TEAE. Almost all patients experienced some sort of TEAE.

Four patient deaths occurred, linked to repeated dosing of JNJ-6420. Two deaths were associated with interstitial lung disease (ILD), one with COVID-19-related respiratory failure, and one with decreased appetite/hypotension.

ILD occurred in patients receiving cumulative doses of 750 μCi or higher.

Thrombocytopenia (low platelet count) was reported in 63% of treatment-emergent adverse events (TEAEs), and ILD in 9%.

Common TEAEs included anemia, lymphopenia, and leukopenia.

Nine patients discontinued treatment.

JNJ-6420 demonstrated a reported PSA50 rate of 45.6%, indicating a positive prostate-specific antigen response associated with prolonged survival.

The drug produced one complete response, two partial responses, and three confirmed objective responses.

Notable clinical, biochemical, and radiographic responses were observed in patients receiving doses of 150 μCi and higher, with durable responses noted up to 112 weeks.

TO MITIGATE RISK: the study recommends a "cumulative dose cap and adaptive dosing schedule'. Evaluation of adaptive dosing is ongoing.

-----
REPORT 2: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical

Link to this report: https://www.statnews.com/2024/05/23/johnson-and-johnson-radiopharmaceuticals-prostate-cancer/

Highlights:

"... An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

"... 18% of participants on a mid-level dose of JnJ’s treatment had a complete or partial response. For comparison, approx. 29.8% of subjects in a Phase 3 trial of Pluvicto responded to the treatment..."

--------
I hope I have accurately represented the information that I found - and I hope this is useful to the Cu6 community.

Expand

This is just an opinion, but JNJ-69086420 will be killed if it hasn’t been already. Big Pharma doesn’t continue programs unless there is clear evidence of superior efficacy - if anything they will kill good therapies too early.
CU6 Price at posting: $4.35 Sentiment: Buy Disclosure: Held
16 Upvote

1 Great analysis

Reply

Top Stories

HMX

Hammer to unlock North Orelia gold play with average recoveries of 94%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Superannuation Essentials: Building Wealth for Your Retirement

CXO

Core Lithium jumps 10% on gold assay hits; drill run expansion

HRE

Deal between Heavy Rare Earths, Havilah hands former SA uranium assets

There are more pages in this discussion • 475 more messages in this thread...

First 149 Last

Add CU6 (ASX) to my watchlist

(20min delay)
Last $6.51		Change -0.275(4.06%)		Mkt cap ! $2.092B

Open	High	Low	Value	Volume
$6.73	$6.75	$6.47	$3.640M	553.6K

Buyers (Bids)

No.	Vol.	Price($)
8	237	$6.50

Sellers (Offers)

Price($)	Vol.	No.
$6.51	5342	13

View Market Depth

No.	Vol.	Price($)
10	270	6.500
4	2520	6.490
9	5357	6.480
5	10265	6.470
4	2387	6.460

Price($)	Vol.	No.
6.510	5315	13
6.520	5009	11
6.530	4516	7
6.540	2668	5
6.550	1357	2

Last trade - 13.25pm 21/10/2024 (20 minute delay)

CU6 (ASX) Chart

This is just an opinion, but JNJ-69086420 will be killed if it...

Hammer to unlock North Orelia gold play with average recoveries of 94%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Superannuation Essentials: Building Wealth for Your Retirement

Core Lithium jumps 10% on gold assay hits; drill run expansion

Deal between Heavy Rare Earths, Havilah hands former SA uranium assets

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

This is just an opinion, but JNJ-69086420 will be killed if it...

Top Stories

Hammer to unlock North Orelia gold play with average recoveries of 94%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Superannuation Essentials: Building Wealth for Your Retirement

Core Lithium jumps 10% on gold assay hits; drill run expansion

Deal between Heavy Rare Earths, Havilah hands former SA uranium assets

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News